CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers. Treatment with Chimeric Antigen Receptor-T cell (CAR-T) therapy is revolutionizing the management of patients with relapsed/refractory...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2023-04-01
|
| Serie: | Current Oncology |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1718-7729/30/4/305 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|